New Hope in Alzheimer’s Treatment: Eli Lilly’s Donanemab Receives CHMP Approval
PharmaGenDRx News Bureau- 06th August, 2025
10:00 AM IST
Donanemab, marketed as Kisunla, developed by Eli Lilly and Company, receives a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of early symptomatic Alzheimer’s Disease in adults. The disease is characterised as a progressive neurodegenerative disorder which impairs memory and cognitive functions with very blunt symptoms in the initial stages before advancing to severe dementia. In upcoming months, the European commission will proceed with the final decision on this drug.
Pratik Jonsson, Executive Vice President and president of Lilly International, said – Donanemab gives a positive response across Europe and it’s a significant milestone for Eli Lilly company. He also added that Donanemab has the potential to cure people living with early symptomatic Alzheimer’s Disease.
In 2020, there were more than 55 million people who were suffering from dementia all over the world. These numbers will almost double every 20 years, so after 2030 , the number of affected people will be near about 78 million, and it will be 139 million in 2050. In Europe more than 6 million people are affected by Alzheimer’s disease, as the population is increasing day by day, the number of affected people is expected to rise to a staggering 14 million by 2030 in Europe.
The positive assessment was mainly based on Clinical Trial data from the TRIALBAZER- ALZ- 2 study, which shows that Donanemab , notably slowed down cognitive decline and decreased the probability of advancing to the next clinical stages of the disease. Donanemab, A New Monoclonal Antibody therapy that targets and removes amyloid plaques in the brain, which are believed to contribute to the treatment of Alzheimer’s Disease.
By Pranoy Chakraborty
